PROGESTAGENS AND ADVANCED BREAST CANCER

Abstract An interim analysis of the clinical responses in a controlled trial of œstrogens, an androgen, or a progestagen in the treatment of advanced breast cancer suggests that the progestagen used (17α-hydroxyprogesterone caproate 250 mg. intramuscularly three times a week) has no place in the management of generalised disease.